June #135 : Seeing Double - by Liz Highleyman

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Jagged Little Pills

Happy Feet

Bunny Business

Playing the Percentages

Soul Survivors

B Careful

In the Running

Seeing Double

Write of Passage

Salad Daze

From Here to Paternity

Summer Share

Papa, Can You Hear Me?

Outside Chance

Send Us the Bill

Climb Every Mountain

Farewell Tour

Hot Dates-June 2007

Agent Provocateur

Mixed (Up) Media

Another AIDS Movie for Philadelphia

Say What?!-June 2007

Attention, K-Y Shoppers

The Next Best Thing to Being There

Getting Crafty

Baggage Claim

Editor's Letter-June 2007

Mailbox-June 2007

Catch of the Month—June 2007

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

June 2007

Seeing Double

by Liz Highleyman

Treatments for hepatitis C begin to mimic those for HIV

For the estimated one-third of HIV-positive folks who also have hep C (HCV), watching drug development is a must. Standard HCV therapy—pegylated interferon (to help the immune system fight C) plus ribavirin (to curb relapse)—has side effects so bad they feel like “the flu from hell,” and works in fewer than half of cases. Experimental meds attack HCV itself, disrupting its reproduction (as HIV meds do to HIV) while causing fewer side effects. The hope: drugs with more oomph but fewer ughs.

One that could be approved in late 2008 is Vertex’s HCV protease inhibitor (PI), telaprevir (VX-950). Alone or with interferon, telaprevir suppresses HCV and by itself hasn’t caused nasty side effects. Other novel meds, including two more PIs and two that inhibit another HCV enzyme, polymerase, are also close to approval.

Further, researchers have found a protein, claudin-1, that HCV uses to enter cells, offering another possible future drug target. As with HIV meds, combining drugs would add punch and delay drug resistance. So look for hep combos that tackle HCV at various life-cycle stages.

In grimmer news, recent studies confirm HCV transmission via sex, not only shared needles. First, outbreaks erupted among HIV-positive gay men in the UK and Europe; this year, a British study found it among HIV-negative gay men too. Sexual transmission is linked to anal sex, fisting, the presence of other STDs and use of non-injected drugs like crystal. If you indulge, reach for condoms and latex gloves. C ya.  

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.